Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Proteomic Profiling of Hsp90 Inhibitors.

Voruganti S, Kline JT, Balch MJ, Rogers J, Matts RL, Hartson SD.

Methods Mol Biol. 2018;1709:139-162. doi: 10.1007/978-1-4939-7477-1_11.

PMID:
29177657
2.

A High-Throughput Screen for Inhibitors of the Hsp90-Chaperone Machine.

Davenport J, Galam L, Matts RL.

Methods Mol Biol. 2018;1709:87-96. doi: 10.1007/978-1-4939-7477-1_7.

PMID:
29177653
3.

Identification of proteins associated with Aha1 in HeLa cells by quantitative proteomics.

Sun L, Hartson SD, Matts RL.

Biochim Biophys Acta. 2015 May;1854(5):365-80. doi: 10.1016/j.bbapap.2015.01.002. Epub 2015 Jan 19.

PMID:
25614414
4.

High-throughput screen of natural product libraries for hsp90 inhibitors.

Davenport J, Balch M, Galam L, Girgis A, Hall J, Blagg BS, Matts RL.

Biology (Basel). 2014 Feb 10;3(1):101-38. doi: 10.3390/biology3010101.

5.

Hsp90-dependent assembly of the DBC2/RhoBTB2-Cullin3 E3-ligase complex.

Manjarrez JR, Sun L, Prince T, Matts RL.

PLoS One. 2014 Mar 7;9(3):e90054. doi: 10.1371/journal.pone.0090054. eCollection 2014.

6.

Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors.

Sadikot T, Swink M, Eskew JD, Brown D, Zhao H, Kusuma BR, Rajewski RA, Blagg BS, Matts RL, Holzbeierlein JM, Vielhauer GA.

Assay Drug Dev Technol. 2013 Oct;11(8):478-88. doi: 10.1089/adt.2012.498. Epub 2013 Oct 15.

7.

The anticancer drug AUY922 generates a proteomics fingerprint that is highly conserved among structurally diverse Hsp90 inhibitors.

Voruganti S, Lacroix JC, Rogers CN, Rogers J, Matts RL, Hartson SD.

J Proteome Res. 2013 Aug 2;12(8):3697-706. doi: 10.1021/pr400321x. Epub 2013 Jun 27.

8.

Characterization of the interaction of Aha1 with components of the Hsp90 chaperone machine and client proteins.

Sun L, Prince T, Manjarrez JR, Scroggins BT, Matts RL.

Biochim Biophys Acta. 2012 Jun;1823(6):1092-101. doi: 10.1016/j.bbamcr.2012.03.014. Epub 2012 Apr 5.

9.

Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.

Eskew JD, Sadikot T, Morales P, Duren A, Dunwiddie I, Swink M, Zhang X, Hembruff S, Donnelly A, Rajewski RA, Blagg BS, Manjarrez JR, Matts RL, Holzbeierlein JM, Vielhauer GA.

BMC Cancer. 2011 Oct 31;11:468. doi: 10.1186/1471-2407-11-468.

10.

Approaches for defining the Hsp90-dependent proteome.

Hartson SD, Matts RL.

Biochim Biophys Acta. 2012 Mar;1823(3):656-67. doi: 10.1016/j.bbamcr.2011.08.013. Epub 2011 Aug 27. Review.

11.

Elucidation of the Hsp90 C-terminal inhibitor binding site.

Matts RL, Dixit A, Peterson LB, Sun L, Voruganti S, Kalyanaraman P, Hartson SD, Verkhivker GM, Blagg BS.

ACS Chem Biol. 2011 Aug 19;6(8):800-7. doi: 10.1021/cb200052x. Epub 2011 May 17.

12.

Gambogic acid, a natural product inhibitor of Hsp90.

Davenport J, Manjarrez JR, Peterson L, Krumm B, Blagg BS, Matts RL.

J Nat Prod. 2011 May 27;74(5):1085-92. doi: 10.1021/np200029q. Epub 2011 Apr 12.

13.

Identification and initial SAR of silybin: an Hsp90 inhibitor.

Zhao H, Brandt GE, Galam L, Matts RL, Blagg BS.

Bioorg Med Chem Lett. 2011 May 1;21(9):2659-64. doi: 10.1016/j.bmcl.2010.12.088. Epub 2010 Dec 28.

PMID:
21273068
14.

A systematic protocol for the characterization of Hsp90 modulators.

Matts RL, Brandt GE, Lu Y, Dixit A, Mollapour M, Wang S, Donnelly AC, Neckers L, Verkhivker G, Blagg BS.

Bioorg Med Chem. 2011 Jan 1;19(1):684-92. doi: 10.1016/j.bmc.2010.10.029. Epub 2010 Oct 19.

15.
16.

KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells.

Shelton SN, Shawgo ME, Matthews SB, Lu Y, Donnelly AC, Szabla K, Tanol M, Vielhauer GA, Rajewski RA, Matts RL, Blagg BS, Robertson JD.

Mol Pharmacol. 2009 Dec;76(6):1314-22. doi: 10.1124/mol.109.058545. Epub 2009 Sep 9.

17.

Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells.

Matthews SB, Vielhauer GA, Manthe CA, Chaguturu VK, Szabla K, Matts RL, Donnelly AC, Blagg BS, Holzbeierlein JM.

Prostate. 2010 Jan 1;70(1):27-36. doi: 10.1002/pros.21035.

18.

Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold.

Hadden MK, Hill SA, Davenport J, Matts RL, Blagg BS.

Bioorg Med Chem. 2009 Jan 15;17(2):634-40. doi: 10.1016/j.bmc.2008.11.064. Epub 2008 Dec 3.

19.

Derrubone, an inhibitor of the Hsp90 protein folding machinery.

Hadden MK, Galam L, Gestwicki JE, Matts RL, Blagg BS.

J Nat Prod. 2007 Dec;70(12):2014-8. Epub 2007 Nov 17.

PMID:
18020309
20.

High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase.

Galam L, Hadden MK, Ma Z, Ye QZ, Yun BG, Blagg BS, Matts RL.

Bioorg Med Chem. 2007 Mar 1;15(5):1939-46. Epub 2007 Jan 4.

21.

Direct interaction of the cell division cycle 37 homolog inhibits endothelial nitric oxide synthase activity.

Harris MB, Bartoli M, Sood SG, Matts RL, Venema RC.

Circ Res. 2006 Feb 17;98(3):335-41. Epub 2006 Jan 12.

PMID:
16410463
22.

Cdk2: a genuine protein kinase client of Hsp90 and Cdc37.

Prince T, Sun L, Matts RL.

Biochemistry. 2005 Nov 22;44(46):15287-95.

PMID:
16285732
23.

Exposure of protein kinase motifs that trigger binding of Hsp90 and Cdc37.

Prince T, Matts RL.

Biochem Biophys Res Commun. 2005 Dec 23;338(3):1447-54. Epub 2005 Oct 26.

PMID:
16269130
24.

Interdomain interactions regulate the activation of the heme-regulated eIF 2 alpha kinase.

Yun BG, Matts JA, Matts RL.

Biochim Biophys Acta. 2005 Sep 15;1725(2):174-81.

PMID:
16109458
25.
26.
27.

Evidence for chaperone heterocomplexes containing both Hsp90 and VCP.

Prince T, Shao J, Matts RL, Hartson SD.

Biochem Biophys Res Commun. 2005 Jun 17;331(4):1331-7.

PMID:
15883021
28.

Definition of protein kinase sequence motifs that trigger high affinity binding of Hsp90 and Cdc37.

Prince T, Matts RL.

J Biol Chem. 2004 Sep 17;279(38):39975-81. Epub 2004 Jul 17.

29.

Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions.

Yun BG, Huang W, Leach N, Hartson SD, Matts RL.

Biochemistry. 2004 Jun 29;43(25):8217-29.

PMID:
15209518
30.

Identification of crucial histidines for heme binding in the N-terminal domain of the heme-regulated eIF2alpha kinase.

Inuzuka T, Yun BG, Ishikawa H, Takahashi S, Hori H, Matts RL, Ishimori K, Morishima I.

J Biol Chem. 2004 Feb 20;279(8):6778-82. Epub 2003 Dec 12.

31.
32.

High affinity binding of Hsp90 is triggered by multiple discrete segments of its kinase clients.

Scroggins BT, Prince T, Shao J, Uma S, Huang W, Guo Y, Yun BG, Hedman K, Matts RL, Hartson SD.

Biochemistry. 2003 Nov 4;42(43):12550-61.

PMID:
14580201
33.

Phosphorylation of serine 13 is required for the proper function of the Hsp90 co-chaperone, Cdc37.

Shao J, Prince T, Hartson SD, Matts RL.

J Biol Chem. 2003 Oct 3;278(40):38117-20. Epub 2003 Aug 20.

34.

NO-induced activation mechanism of the heme-regulated eIF2alpha kinase.

Ishikawa H, Yun BG, Takahashi S, Hori H, Matts RL, Ishimori K, Morishima I.

J Am Chem Soc. 2002 Nov 20;124(46):13696-7.

PMID:
12431098
35.
36.

Differential inhibition of Hsc70 activities by two Hsc70-binding peptides.

Thulasiraman V, Yun BG, Uma S, Gu Y, Scroggins BT, Matts RL.

Biochemistry. 2002 Mar 19;41(11):3742-53.

PMID:
11888292
37.

The molecular chaperone Hsp90 is required for signal transduction by wild-type Hck and maintenance of its constitutively active counterpart.

Scholz GM, Hartson SD, Cartledge K, Volk L, Matts RL, Dunn AR.

Cell Growth Differ. 2001 Aug;12(8):409-17.

38.
39.

Hsp90 regulates p50(cdc37) function during the biogenesis of the activeconformation of the heme-regulated eIF2 alpha kinase.

Shao J, Grammatikakis N, Scroggins BT, Uma S, Huang W, Chen JJ, Hartson SD, Matts RL.

J Biol Chem. 2001 Jan 5;276(1):206-14.

40.

p50(Cdc37) can buffer the temperature-sensitive properties of a mutant of Hck.

Scholz G, Hartson SD, Cartledge K, Hall N, Shao J, Dunn AR, Matts RL.

Mol Cell Biol. 2000 Sep;20(18):6984-95.

41.

p50(cdc37) is a nonexclusive Hsp90 cohort which participates intimately in Hsp90-mediated folding of immature kinase molecules.

Hartson SD, Irwin AD, Shao J, Scroggins BT, Volk L, Huang W, Matts RL.

Biochemistry. 2000 Jun 27;39(25):7631-44.

PMID:
10858314
42.

Identification of caspase 3-mediated cleavage and functional alteration of eukaryotic initiation factor 2alpha in apoptosis.

Marissen WE, Guo Y, Thomas AA, Matts RL, Lloyd RE.

J Biol Chem. 2000 Mar 31;275(13):9314-23.

43.

Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases.

Yorgin PD, Hartson SD, Fellah AM, Scroggins BT, Huang W, Katsanis E, Couchman JM, Matts RL, Whitesell L.

J Immunol. 2000 Mar 15;164(6):2915-23.

44.

Two heme-binding domains of heme-regulated eukaryotic initiation factor-2alpha kinase. N terminus and kinase insertion.

Rafie-Kolpin M, Chefalo PJ, Hussain Z, Hahn J, Uma S, Matts RL, Chen JJ.

J Biol Chem. 2000 Feb 18;275(7):5171-8.

45.

The N-terminal region of the heme-regulated eIF2alpha kinase is an autonomous heme binding domain.

Uma S, Matts RL, Guo Y, White S, Chen JJ.

Eur J Biochem. 2000 Jan;267(2):498-506.

47.

Disruption of zebrafish somite development by pharmacologic inhibition of Hsp90.

Lele Z, Hartson SD, Martin CC, Whitesell L, Matts RL, Krone PH.

Dev Biol. 1999 Jun 1;210(1):56-70.

48.

Molybdate inhibits hsp90, induces structural changes in its C-terminal domain, and alters its interactions with substrates.

Hartson SD, Thulasiraman V, Huang W, Whitesell L, Matts RL.

Biochemistry. 1999 Mar 23;38(12):3837-49.

PMID:
10090774
49.

Evidence that Hsc70 negatively modulates the activation of the heme-regulated eIF-2alpha kinase in rabbit reticulocyte lysate.

Thulasiraman V, Xu Z, Uma S, Gu Y, Chen JJ, Matts RL.

Eur J Biochem. 1998 Aug 1;255(3):552-62.

50.

Luciferase renaturation assays of chaperones and chaperone antagonists.

Thulasiraman V, Matts RL.

Methods Mol Biol. 1998;102:129-41. No abstract available.

PMID:
9680615

Supplemental Content

Loading ...
Support Center